Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 6/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | EP300 | Q09472 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25845603 | 0.95 | NTSR1 (0.54) | OPRD1SLC6A2NTSR1NTSR2F2 | |
| SCHEMBL25846293 | 0.95 | NTSR1 (0.54) | OPRD1SLC6A2NTSR1NTSR2F2 | |
| SCHEMBL14930602 | 0.93 | AGTR2 (0.55) | SLC6A2CALCRLNTSR1NTSR2F2 | |
| SCHEMBL25845492 | 0.93 | NTSR1 (0.54) | OPRD1SLC6A2NTSR1NTSR2F2 | |
| SCHEMBL25845490 | 0.89 | SLC6A2 (0.55) | SLC6A2CALCRLNTSR1NTSR2F2 | |
| SCHEMBL25845686 | 0.87 | NMBR (0.58) | F2 | |
| SCHEMBL14930600 | 0.87 | NMBR (0.58) | F2 | |
| SCHEMBL14930601 | 0.87 | NMBR (0.58) | F2 | |
| SCHEMBL22872738 | 0.86 | NPY1R (0.61) | — | |
| SCHEMBL31233798 | 0.85 | SLC6A2 (0.63) | SLC6A2CALCRLNTSR1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708393-B2 | Targeted non-invasive imaging probes of EGFR expressing cells | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708393-B2 | Targeted non-invasive imaging probes of EGFR expressing cells | EGFR, ERBB2, ERBB3 | OPRD1 3041/4885SLC6A2 2289/4885CALCRL 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.